Cost effectiveness of interventions to improve adherence to statin therapy in ASCVD patients in the United States
- PMID: 31496665
- PMCID: PMC6700656
- DOI: 10.2147/PPA.S213258
Cost effectiveness of interventions to improve adherence to statin therapy in ASCVD patients in the United States
Abstract
Introduction: Cardiovascular disease (CVD) is the leading cause of death in the United States, and high cholesterol is a leading risk factor for CVD. While statins are effective at reducing cholesterol, they are frequently underused in patients at highest risk of CVD. The objective of this study was to identify interventions which may improve adherence to statins and to assess their cost effectiveness within the US Medicare population.
Methods: A literature review was undertaken to identify interventions to improve adherence in patients with CVD at highest risk of a recurrent event and to quantify non-adherence and the consequences of non-adherence to statins in this population. A Markov cost-utility model was developed to assess the cost effectiveness of these interventions.
Results: Ten adherence interventions were identified in the literature, with 6 demonstrating statistically significant improvement in adherence. The six interventions were disease management, interactive voice response, nurse counselling, discharge letter, nurse/dietician counselling and electronic pill bottle with feedback. The model found the cost effectiveness of an intervention was highly dependent on its effectiveness and costs. Incremental cost effectiveness ratios ranged from $27,545/QALY for discharge letter with large adherence gain to $130,399/QALY for disease management program with small adherence gain.
Conclusion: Some interventions to improve adherence have been shown to be effective, but little attention has been paid to the costs. Further studies on adherence interventions should include economic evaluations.
Keywords: adherence; cardiovascular disease; cost-effectiveness; statins.
Conflict of interest statement
Ms. Shannon Armstrong is an employee and shareholder of the Medicines Company. The authors report no other conflicts of interest in this work.
Figures





Similar articles
-
Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.Clin Ther. 2009 Dec;31(12):2919-30; discussion 2916-8. doi: 10.1016/j.clinthera.2009.12.013. Clin Ther. 2009. PMID: 20110032
-
Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.JAMA. 2015 Jul 14;314(2):142-50. doi: 10.1001/jama.2015.6822. JAMA. 2015. PMID: 26172894 Free PMC article.
-
Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.Clin Cardiol. 2016 Jun;39(6):313-20. doi: 10.1002/clc.22535. Epub 2016 Apr 19. Clin Cardiol. 2016. PMID: 27092712 Free PMC article.
-
The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications.Value Health. 2010 Sep-Oct;13(6):685-94. doi: 10.1111/j.1524-4733.2010.00774.x. Value Health. 2010. PMID: 20825627 Review.
-
Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease : A Systematic Review for the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Management of Dyslipidemia.Ann Intern Med. 2020 Nov 17;173(10):806-812. doi: 10.7326/M20-4680. Epub 2020 Sep 22. Ann Intern Med. 2020. PMID: 32956601
Cited by
-
Long-Term Benefit and Withdrawal Effect of Statins After Percutaneous Coronary Intervention: A Nationwide Population-Based Cohort Study.Patient Prefer Adherence. 2020 Apr 5;14:717-724. doi: 10.2147/PPA.S245324. eCollection 2020. Patient Prefer Adherence. 2020. PMID: 32308376 Free PMC article.
-
Direct Healthcare Costs by Level of Adherence of a Real-World Population of Statin Users in Italy.Clinicoecon Outcomes Res. 2022 Mar 10;14:139-147. doi: 10.2147/CEOR.S345852. eCollection 2022. Clinicoecon Outcomes Res. 2022. PMID: 35299992 Free PMC article.
-
Real-world evaluation of the impact of statin intensity on adherence and persistence to therapy: A Scottish population-based study.Br J Clin Pharmacol. 2020 Dec;86(12):2349-2361. doi: 10.1111/bcp.14333. Epub 2020 May 30. Br J Clin Pharmacol. 2020. PMID: 32353163 Free PMC article.
References
-
- Khavjou O, Phelps D, Leib A. Cardiovascular disease burden: a costly burden for America. Am Heart Assoc. 2016.
-
- Centers for Disease Control and Prevention. Heart Disease Facts. https://www.cdc.gov/heartdisease/facts.htm. Accessed October 3, 2016.
-
- Centers for Disease Control and Prevention. High Cholesterol in the United States. http://www.cdc.gov/cholesterol/facts.htm. Accessed October3, 2016.
-
- Baigent C, Keech A, Kearney PM, et al.; Cholesterol Treatment Trialists (CCT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278. doi:10.1016/S0140-6736(05)67394-1 - DOI - PubMed
-
- Consumer Reports. Best Buy Drugs: Evaluating Statin Drugs to Treat High Cholesterol and Heart Disease. New York, NY: Consumer Reports;2014.
LinkOut - more resources
Full Text Sources